A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Eli Lilly and Company
University of Pittsburgh
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
OncoC4, Inc.
Jazz Pharmaceuticals
Revolution Medicines, Inc.
Bayer
USWM, LLC (dba US WorldMeds)
Arcus Biosciences, Inc.
SystImmune Inc.
Institut Paoli-Calmettes
Sutro Biopharma, Inc.
Neonc Technologies, Inc.
ViroMissile, Inc.
Duke University
Qurient Co., Ltd.
Duke University
Essen Biotech
Revolution Medicines, Inc.
SystImmune Inc.
Daiichi Sankyo
Perspective Therapeutics
Second Life Therapeutics
Novartis
Tanabe Pharma America, Inc.
University Health Network, Toronto
NeoTX Therapeutics Ltd.
CRISPR Therapeutics
Laekna Limited
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
Arcus Biosciences, Inc.
Dana-Farber Cancer Institute
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Cancer Research UK
Novita Pharmaceuticals, Inc.